hepat
c
viru
hcv
infect
world
popul
lead
caus
liver
diseas
liver
transplant
pose
seriou
grow
worldwid
public
health
problem
partial
address
introduct
new
antivir
therapi
howev
treatment
prevent
reinfect
particularli
high
risk
popul
introduct
hcv
vaccin
predict
use
simul
model
high
risk
popul
signific
effect
reduc
incid
hcv
vaccin
efficaci
target
highrisk
intraven
drug
user
could
dramat
reduc
hcv
incid
popul
viru
like
particl
vlp
compos
viral
structur
protein
selfassembl
noninfecti
particl
lack
genet
materi
resembl
nativ
virus
thu
vlp
repres
safe
highli
immunogen
vaccin
deliveri
platform
abl
induc
potent
adapt
immun
respons
current
mani
vlpbase
vaccin
enter
clinic
trial
licens
vlp
vaccin
hepat
b
viru
hbv
human
papilloma
viru
hpv
use
mani
year
hcv
core
protein
selfassembl
immunogen
vlp
inclus
hcv
antigen
heterogen
chimer
vlp
also
promis
approach
vlp
produc
use
differ
express
system
bacteri
yeast
mammalian
plant
insect
cell
paper
review
hcv
vlpbase
vaccin
immunogen
anim
model
well
differ
express
system
use
product
hepat
c
viru
envelop
posit
sens
singlestrand
rna
viru
infect
million
peopl
world
popul
bartenschlag
et
al
major
individu
infect
hcv
develop
chronic
hepat
proport
develop
cirrhosi
liver
carcinoma
hcv
remain
common
reason
liver
transplant
worldwid
bartenschlag
et
al
introduct
highli
effect
direct
act
antivir
daa
design
inhibit
function
specif
nonstructur
ns
viral
protein
critic
viral
replic
result
high
cure
rate
patient
shorten
durat
treatment
associ
rel
side
effect
howev
use
daa
limit
high
cost
us
treatment
cours
et
al
rosenth
graham
consequ
estim
approxim
diagnos
hepat
c
viru
infect
treat
annual
australia
commonwealth
australia
global
pool
hcv
infect
person
increas
million
new
infect
year
gower
et
al
furthermor
world
health
organ
estim
infect
hcv
awar
diagnosi
diagnos
hcv
place
treatment
worldwid
world
health
organ
consequ
develop
safe
effect
inexpens
hcv
vaccin
therefor
necessari
control
global
infect
reduc
financi
burden
healthcar
system
howev
develop
effect
hcv
vaccin
hinder
sever
factor
includ
high
genet
variabl
viru
genom
give
rise
escap
mutant
evad
cellular
humor
host
immun
respons
moreov
current
suitabl
small
anim
model
avail
mimic
hcv
infect
human
furthermor
human
chimpanze
previous
treat
cure
hepat
c
could
reinfect
reexposur
viru
farci
et
al
bukh
et
al
convers
optim
develop
success
hcv
vaccin
might
possibl
proport
infect
individu
clear
viru
natur
develop
immun
abl
reduc
durat
viremia
viral
load
subsequ
infect
princ
halliday
et
al
understand
antivir
immun
respons
individu
chimpanze
model
elucid
key
mechan
thought
contribut
control
hcv
infect
demonstr
induct
mainten
strong
cell
immun
respons
variou
viral
epitop
associ
resolut
hcv
infect
forn
et
al
thimm
et
al
thimm
et
al
youn
et
al
thought
cellmedi
respons
alon
suffici
time
induct
crossneutr
antibodi
nab
import
protect
viral
clearanc
farci
et
al
yu
et
al
osburn
et
al
licens
viral
vaccin
polioviru
induc
nab
viral
surfac
protein
provid
protect
howev
despit
develop
effici
system
hcv
cultur
lindenbach
et
al
wakita
et
al
zhong
et
al
still
feasibl
gener
vaccin
base
kill
liveattenu
hcv
due
potenti
danger
associ
use
particl
forn
et
al
shortcom
led
develop
experiment
vaccin
includ
dna
vaccin
recombin
nonpathogen
vector
protein
viru
like
particl
vlp
despit
mani
obstacl
imped
develop
vaccin
sever
studi
involv
vlpbase
vaccin
candid
alreadi
gener
promis
result
preclin
studi
murata
et
al
jourdan
et
al
elmowalid
et
al
patient
et
al
roy
noad
garron
et
al
vicent
et
al
bellier
klatzmann
huret
et
al
beaumont
roingeard
articl
review
hcv
vaccin
strategi
base
homolog
heterolog
hcv
vlp
tabl
plasmid
dna
viral
vector
encod
hcvvlp
tabl
well
variou
express
system
tabl
util
product
hcv
vlp
vaccin
viru
like
particl
attract
candid
elicit
nab
respons
structur
resembl
much
safer
wildtyp
viru
deriv
jourdan
et
al
torresi
et
al
roy
noad
addit
hepat
b
viru
hbv
hpv
vlp
vaccin
vlp
approach
use
recent
develop
chikungunya
viru
vaccin
effect
nonhuman
primat
akahata
et
al
selfassembl
hcvlike
particl
hcvlp
report
gener
hcvvlp
biophys
ultrastructur
antigen
properti
similar
put
virion
baumert
et
al
baumert
et
al
hcvlp
gener
cell
recombin
baculoviru
encod
hcv
core
protein
immun
recombin
hcvlp
reveal
induc
strong
broad
polyclon
cellular
humor
immun
mice
baumert
et
al
lechmann
et
al
murata
et
al
well
chimpanze
tabl
elmowalid
et
al
immunogen
hcvlp
strongli
depend
particl
format
vaccin
heatdenatur
particl
result
reduc
antigenspecif
tcell
antibodi
respons
lechmann
et
al
propos
hcvlp
abil
interact
specif
dendrit
cell
dc
result
activ
effici
antigen
present
contrast
denatur
hcvlp
murata
et
al
barth
et
al
hepat
c
viruslp
produc
mammalian
cell
use
adenovirusbas
system
gener
particl
report
resembl
nativ
virion
morpholog
chua
et
al
kumar
et
al
vaccin
adenovirusderiv
hcvlp
combin
anion
selfadjuv
lipopeptid
contain
tolllik
receptor
tlr
agonist
pam
cy
e
pam
cy
result
signific
hcvlp
antibodi
respons
mice
chua
et
al
three
dose
nonadjuv
tradit
alumadjuv
hcvlp
essenti
reach
similar
hcvlpand
antibodi
titer
induc
singl
dose
hcvlpe
pam
cy
addit
antibodi
neutral
bind
uptak
vlp
human
hepatocellular
carcinoma
cell
cell
cultur
deriv
hcv
hcvcc
signific
number
antigenspecif
antibodi
secret
cell
also
detect
spleen
hcvlpe
pam
cy
vaccin
mice
correl
previou
result
chua
et
al
moreov
vaccin
human
leukocyt
antigen
hla
transgen
mice
vaccin
gener
higher
hcvlpspecif
respons
compar
nonadjuv
hcvlp
chua
et
al
heterolog
primeboost
strategi
immun
recombin
adenovirus
encod
hcv
structur
protein
final
booster
follow
prime
hcvlp
result
enhanc
antibodi
tcell
respons
kumar
et
al
addit
sera
immun
mice
reduc
bind
vlp
strain
hcv
cell
demonstr
presenc
nab
kumar
et
al
even
though
differ
studi
provid
evid
hcvderiv
vlp
promis
vaccin
strategi
capabl
elicit
hcvspecif
humor
cellular
immun
addit
studi
requir
determin
best
induc
highli
protect
longlast
immun
respons
hepat
b
virusderiv
vlp
evalu
carrier
abl
present
heterolog
epitop
chackerian
includ
hcvderiv
antigen
one
approach
chimer
vlp
gener
fuse
target
antigen
viral
capsid
protein
cp
capabl
selfassembl
vlp
tabl
protein
hbv
surfac
antigen
hbsag
report
selfassembl
potent
noninfecti
secret
subvir
particl
use
commerci
vaccin
hepat
b
three
decad
hbsag
particl
design
carrier
foreign
epitop
insert
cterminu
extern
hydrophil
loop
hbsag
patient
et
al
hcvspecif
epitop
deriv
protein
hypervari
region
insert
recombin
hbsag
vlp
secret
transfect
mammalian
cell
netter
et
al
vietheer
et
al
particl
recogn
human
antihcvposit
serum
contain
antibodi
suggest
antigen
structur
region
express
particl
surfac
close
resembl
authent
structur
netter
et
al
subsequ
specif
antibodi
respons
effici
induc
netter
et
al
vietheer
et
al
furthermor
vaccin
cocktail
hbsag
vlp
contain
epitop
either
strain
induc
antibodi
epitop
result
higher
titer
gener
immun
individu
vlp
suggest
synergist
effect
netter
et
al
insert
fulllength
hcv
envelop
protein
hbsag
vlp
also
shown
result
chimer
hbvhcv
particl
similar
size
shape
wildtyp
hbsag
subvir
particl
patient
et
al
immun
rabbit
hbvhcv
vlp
result
high
titer
crossnab
abil
neutral
variou
hcv
genotyp
beaumont
et
al
recent
immunogen
chimer
hbsag
vlp
express
protein
separ
immunogen
compar
hbsag
vlp
bear
heterodim
beaumont
et
al
humor
respons
induc
anim
vaccin
hbsag
vlp
express
heterodim
conform
significantli
reduc
compar
respons
rabbit
immun
hbsag
vlp
express
separ
beaumont
et
al
addit
antibodi
show
increas
crossneutr
variou
genotyp
heterolog
hcv
strain
result
confirm
previou
observ
garron
et
al
heterodim
less
immunogen
possibl
due
conform
fold
surfac
hbsag
particl
contribut
mask
certain
immunodomin
epitop
furthermor
although
fold
complex
surfac
hbsag
particl
demonstr
structur
dimer
particl
might
repres
dimer
surfac
nativ
hcv
virion
nonetheless
particl
also
gener
signific
level
hbsspecif
antibodi
support
develop
bival
hbvhcv
prophylact
vaccin
capabl
prevent
primari
infect
either
two
virus
beaumont
et
al
administr
chimer
hbsagshcv
vlp
demonstr
mice
netter
et
al
rabbit
beaumont
roingeard
preexist
antihbsag
antibodi
success
gener
antihcv
antibodi
therefor
chimer
particl
use
popul
preexist
immun
hbv
strategi
induc
protect
immun
hcv
encourag
result
obtain
far
support
develop
hbvderiv
vlp
vaccin
howev
addit
studi
need
assess
immunogen
chimer
hbvhcv
particl
larger
anim
model
also
develop
mean
increas
broadli
neutral
characterist
result
nab
hbv
core
protein
hbc
natur
self
assembl
dimer
subsequ
vlp
use
vlp
carrier
three
decad
clark
et
al
borisova
et
al
insert
foreign
sequenc
hbc
gene
imped
particl
format
make
hbc
suitabl
develop
vlp
vaccin
display
foreign
antigen
ulrich
et
al
sominskaya
et
al
segment
hcv
gene
encod
core
aa
aa
protein
contain
band
tcell
epitop
fuse
end
hbc
gene
gener
chimer
hbchcv
vlp
mihailova
et
al
two
protein
chosen
immunogen
induct
broad
tcell
respons
variou
hcv
protein
includ
core
typic
associ
resolut
control
hcv
infect
administr
hbchcv
core
particl
induc
moder
low
antibodi
level
prolif
respons
tcell
hcv
core
epitop
vaccin
hbchcv
particl
induc
signific
level
antibodi
prolif
respons
hcv
epitop
mihailova
et
al
howev
antibodi
core
believ
prophylact
valu
gener
consid
protect
natur
hcv
infect
furthermor
variat
immun
respons
chimer
particl
might
caus
altern
present
insert
hcv
sequenc
context
chimer
particl
mihailova
et
al
similarli
chimer
vlp
carri
virusneutr
hbv
epitop
highli
conserv
ntermin
hcv
core
epitop
c
terminu
truncat
hbc
protein
success
gener
sominskaya
et
al
vaccin
particl
induc
high
cell
immun
similar
induc
monoval
hbchcv
core
particl
induc
low
antibodi
respons
hcv
core
epitop
argu
core
epitop
locat
c
terminu
expos
surfac
vlp
therefor
abl
induc
strong
antibodi
respons
sominskaya
et
al
highlight
import
posit
insert
epitop
within
hbc
term
particl
humor
immunogen
insert
larger
amino
acid
sequenc
would
benefici
develop
product
multival
hcv
vaccin
carri
larger
number
epitop
coupl
one
frontier
microbiolog
wwwfrontiersinorg
carrier
molecul
facilit
proper
fold
conform
epitop
import
gener
nab
howev
insert
larger
insert
within
hbc
particl
might
affect
abil
chimer
particl
drive
insertspecif
immun
respons
variou
studi
report
contradictori
result
regard
maximum
insert
capac
hbc
without
affect
immunogen
insert
antigen
hbc
abil
success
form
particl
maximum
aa
human
immunodefici
viru
kalam
et
al
gag
protein
report
toler
fusion
aa
gag
protein
downstream
aa
prevent
selfassembl
chimer
hbc
particl
ulrich
et
al
yoshikawa
et
al
hand
report
success
format
hbc
particl
carri
aa
segment
compos
four
copi
aa
sequenc
deriv
hcv
core
protein
howev
immunogen
particl
assess
vivo
model
complet
glycoprotein
also
display
nativ
conform
surfac
retrovir
particl
process
known
pseudotyp
infecti
hcvpp
engin
pseudotyp
hcv
glycoprotein
onto
murin
leukemia
viru
mlv
gag
retrovir
core
particl
use
comprehens
studi
earli
event
hcv
infect
well
role
put
hcv
receptor
bartosch
et
al
particl
also
commonli
use
detect
measur
antihcv
nab
hcv
patient
bartosch
et
al
drummer
et
al
hcvpseudotyp
retrovirusderiv
vlp
devoid
genom
hcvretro
vlp
propos
vaccin
platform
studi
molecular
structur
pseudoparticl
describ
hcvpp
hcvretro
vlp
regular
nm
spheric
structur
compris
dens
retrovir
nucleocapsid
surround
lipid
bilay
bonnaf
et
al
garron
et
al
follow
prime
hcvrecombin
viral
vector
vlp
pseudotyp
andor
hcv
glycoprotein
gener
signific
andor
antibodi
titer
mice
macaqu
garron
et
al
highlight
difficulti
induc
antibodi
respons
consist
find
antibodi
gener
detect
low
level
patient
lerouxroel
et
al
pestka
et
al
regimen
examin
vlp
induc
signific
level
antibodi
gener
provid
dissoci
importantli
boost
retrovirusderiv
vlp
heterolog
primeboost
combin
plasmoretrovlp
rais
nab
hcv
genotyp
crossneutr
five
genotypesstrain
huret
et
al
challeng
experi
conduct
assess
antihcv
potenc
hcvretro
vlp
overal
retrovirusderiv
vlp
pseudotyp
assort
viru
envelop
repres
versatil
effici
platform
vaccin
hcv
also
major
infecti
diseas
hivaid
yellow
fever
dengu
fever
howev
despit
encourag
result
use
anim
retrovir
particl
valid
safe
effect
prevent
vaccin
human
scale
manufactur
process
may
present
limit
factor
develop
recombin
retrovirusbas
hcv
vlp
vaccin
recombin
vesicular
stomat
viru
rvsv
shown
effect
express
vector
number
differ
vaccin
strategi
tabl
schnell
et
al
kretzschmar
et
al
sever
advantag
use
rvsv
encod
foreign
viral
protein
vaccin
candid
viru
low
seropreval
commun
pathogen
human
simpl
genom
five
gene
n
p
g
l
undergo
reassort
integr
johnson
et
al
field
hawkin
ezel
et
al
recombin
vsv
evalu
candid
hcv
vaccin
encod
hcv
core
protein
selfassembl
hcv
vlp
vsvhcvvlp
babi
hamster
kidney
fibroblast
cell
ezel
et
al
vsvhcvvlp
show
similar
ultrastructur
properti
hcv
virion
ezel
et
al
vaccin
particl
induc
core
cell
mediat
respons
well
antibodi
respons
ezel
et
al
howev
argu
particl
may
repres
endogen
virus
cell
known
intracistern
rtype
particl
rather
complet
bud
hcvlike
particl
blanchard
et
al
subsequ
demonstr
express
hcv
replicationcompet
defect
gproteindelet
vsv
vector
result
correctli
fold
heterodim
majid
et
al
nevertheless
studi
assess
express
envelop
protein
provid
detail
character
form
vsvhcvvlp
immun
rvsv
result
signific
cell
respons
core
along
anticor
antibodi
respons
ezel
et
al
majid
et
al
neutral
antibodi
respons
assess
howev
immun
rvsv
protect
mice
format
tumor
express
hcv
show
well
tcell
respons
recombin
vsv
express
hcv
structur
protein
repres
versatil
tool
vaccin
develop
use
vector
product
hcv
vlp
mammalian
cell
also
vaccin
candid
recent
effect
ebola
vaccin
candid
rvsvzebov
regul
et
al
compris
liveattenu
vsv
encod
ebola
viru
glycoprotein
prevent
ebola
viru
diseas
recent
diagnos
patient
contact
contact
contact
elsherif
et
al
halperin
et
al
henaorestrepo
et
al
provid
hope
develop
vlpbase
hcv
vaccin
use
strategi
howev
studi
requir
better
character
improv
product
vsvhcvvlp
protect
immun
gener
rvsv
encod
hcv
core
also
need
evalu
particl
use
vaccin
hcv
infect
dna
plasmid
gener
recombin
retrovlp
plasmoretrovlp
bellier
et
al
bellier
et
al
desjardin
et
al
repres
hcv
genet
vaccin
circumv
vitro
product
purif
retrovlp
plasmoretrovlp
engin
produc
situ
retrovlp
pseudotyp
protein
vivo
deliveri
dna
tabl
strategi
combin
benefit
dna
vaccin
eas
develop
lowcost
largescal
product
stabil
immunostimulatori
properti
vlp
circumv
vitro
product
vlp
vaccin
shown
administr
plasmoretrovlp
result
induct
significantli
higher
antigenspecif
respons
antivir
immun
protect
plasmid
mutat
prevent
plasmoretrovlp
assembl
bellier
et
al
bellier
et
al
also
shown
heterolog
primeboost
immun
strategi
hcvplasmoretrovlp
superior
immunogen
boost
cellular
humor
immun
respons
prime
anim
plasmid
unabl
form
retrovlp
bellier
et
al
desjardin
et
al
combin
two
plasmoretrovlp
vaccin
follow
boost
ex
vivo
produc
vlp
shown
induc
hcvspecif
cellmedi
respons
nab
huret
et
al
furthermor
vaccin
cocktail
plasmoretrovlp
pseudotyp
hcv
genotyp
andor
display
antigen
cp
result
immun
respons
five
hcv
genotyp
huret
et
al
major
advantag
plasmoretrovlp
readminist
sequenti
vaccin
without
concern
preexist
vectorassoci
immun
bellier
et
al
dnabas
vaccin
howev
gener
induc
rel
weak
immun
respons
antigen
therefor
regard
inferior
compar
tradit
vaccin
subunit
vaccin
even
strategi
requir
boost
immun
purifi
vlp
maximum
activ
deliveri
rout
andor
method
dnabas
vaccin
also
critic
factor
determin
vaccin
outcom
vsvg
specif
plasmoretrovlp
shown
induc
higher
level
vsvgspecif
humor
cell
mediat
immun
respons
follow
administr
needlefre
intraderm
id
inject
compar
immun
gene
gun
bellier
et
al
addit
needlefre
id
coinject
cytokin
gene
cpg
sequenc
significantli
increas
vsvgspecif
nab
level
bellier
et
al
therefor
attempt
direct
toward
optim
deliveri
method
dnabas
vlp
vaccin
addit
codeliveri
novel
genet
adjuv
maximum
immun
stimul
togeth
result
show
plasmoretrovlp
flexibl
platform
induc
humor
cellular
immun
homolog
heterolog
primeboost
immun
improv
strategi
could
use
promis
approach
gener
enhanc
immun
respons
hcv
viru
like
particl
deriv
plant
virus
also
emerg
promis
strategi
develop
viral
vaccin
papaya
mosaic
viru
papmv
cp
trigger
much
interest
epitop
present
system
sever
hundr
unit
papmv
cp
report
assembl
organ
repetit
manner
particl
rang
nm
length
follow
express
escherichia
coli
tremblay
et
al
recombin
multimer
papmv
vaccin
platform
express
peptid
fuse
ctermin
papmv
cp
shown
trigger
strong
humor
immun
respons
mice
last
day
cp
epitop
tabl
deni
et
al
notabl
platform
less
effect
inocul
monomer
protein
confirm
observ
immunogen
strongli
depend
repetit
organ
antigen
deni
et
al
vlp
platform
face
challeng
might
limit
clinic
develop
vaccin
includ
presenc
bacteri
rna
use
scaffold
papmv
cp
selfassembl
tremblay
et
al
well
possibl
antigen
fusion
might
alter
antigen
conform
interfer
protein
assembl
vlp
format
mani
express
system
product
vlp
current
use
includ
variou
speci
yeast
saccharomyc
cerevisia
cerevisia
pichia
pastori
p
pastori
bacteria
mainli
e
coli
baculoviru
express
vectorinsect
cell
system
bevsic
variou
mammalian
cell
line
well
variou
plant
tobacco
lettuc
leav
tabl
product
system
use
depend
need
retain
consist
origin
vlp
format
post
translat
modif
ptm
eg
glycosyl
phosphoryl
significantli
reduc
product
time
cost
product
system
advantag
drawback
discuss
briefli
bacteri
system
commonli
use
system
manufactur
recombin
protein
use
produc
nonenvelop
hcv
vlp
e
colideriv
hcv
core
protein
selfassembl
vitro
particl
approxim
nm
diamet
kunkel
et
al
lorenzo
et
al
hand
produc
vlp
e
coli
follow
express
truncat
hcv
core
protein
consist
first
amino
acid
similarli
recombin
papmv
cp
vlp
also
produc
follow
express
e
coli
deni
et
al
rioux
et
al
howev
sever
factor
includ
lack
mammalianlik
ptm
system
mean
platform
prefer
vlp
product
tabl
addit
downstream
process
vlp
compromis
presenc
host
cell
deriv
toxin
heat
shock
protein
chaperon
protein
increas
final
product
cost
zhang
et
al
lai
middelberg
yeast
anoth
wellestablish
platform
use
recombin
protein
express
vlp
product
four
licens
vlpbase
vaccin
engerixb
r
hepavaxgen
r
recombivax
hb
r
gardasil
r
merck
co
manufactur
use
system
entir
hcv
core
protein
express
methylotroph
p
pastori
form
particl
similar
structur
properti
nativ
matur
hcv
nucleocapsid
particl
success
recogn
serum
persist
infect
hcv
patient
recent
vlp
nm
diamet
gener
follow
express
recombin
hcv
protein
p
pastori
abl
effici
induc
antibodi
rabbit
fazlalipour
et
al
howev
concern
appropri
protein
process
protein
fold
post
translat
modif
may
direct
choic
toward
altern
product
system
acostarivero
et
al
kushnir
et
al
mammalian
cell
express
system
favor
capabl
perform
appropri
complex
mammaliantyp
ptm
authent
assembl
recombin
protein
chua
et
al
earnestsilveira
et
al
kumar
et
al
variou
hcv
vlp
vaccin
candid
success
produc
mammalian
cell
includ
chines
hamster
ovari
cho
human
embryon
kidney
hek
cell
tabl
immun
recombin
hcv
envelop
glycoprotein
produc
mammalian
cell
protect
chimpanze
effect
compar
produc
yeast
insect
cell
challeng
homolog
hcv
isol
choo
et
al
similarli
mammalian
cellderiv
recombin
envelop
protein
report
bind
strongli
human
cell
compar
produc
yeast
insect
cell
rosa
et
al
recent
vlp
produc
mammalian
cell
found
immunogen
vlp
boost
base
heterolog
strategi
compar
vlp
produc
use
baculovirusinsect
cell
system
kumar
et
al
avoid
deleteri
effect
cesium
chlorid
cscl
use
iodixanol
ultracentrifug
stir
cell
ultrafiltr
result
product
larg
quantiti
hcv
vlp
variou
genotyp
strategi
manufactur
quadrival
mammalian
cell
deriv
hcv
vlp
vaccin
earnestsilveira
et
al
b
plant
product
platform
mani
advantag
compar
mammalian
cell
tabl
plantderiv
vlp
offer
new
approach
oral
deliveri
vaccin
plant
express
system
highli
scalabl
econom
free
mammalian
pathogen
addit
plant
product
system
possess
eukaryoticlik
protein
fold
ptm
similar
mammalian
cell
mett
et
al
yusibov
rabindran
kushnir
et
al
plant
express
system
suitabl
product
nonenvelop
envelop
vlp
daoust
et
al
santi
et
al
tobacco
mosaic
viru
tmv
deriv
vector
encod
contain
hcv
neutral
epitop
fuse
cterminu
b
subunit
cholera
toxin
ctb
use
infect
tobacco
plant
nicotiana
benthamiana
nemchinov
et
al
rybicki
infect
plant
success
gener
tmv
particl
express
nemchinov
et
al
plantderiv
react
monoclon
antibodi
sera
hcvposit
individu
infect
four
major
genotyp
hcv
inocul
mice
plant
extract
result
induct
antictb
antibodi
capabl
specif
bind
hcv
vlp
nemchinov
et
al
plantderiv
hcv
vaccin
reduc
manufactur
cost
associ
product
convent
vaccin
vaccin
administ
edibl
plant
part
would
particularli
help
reduc
incid
hcv
develop
world
howev
date
plantderiv
vlp
licens
human
use
addit
dosag
requir
effect
vaccin
might
vari
depend
plant
use
ripe
fruit
quantiti
food
consum
therefor
administr
edibl
vaccin
requir
standard
evalu
dosag
requir
effect
vaccin
also
certain
plant
fruit
gener
eaten
raw
cook
would
result
denatur
protein
reduct
immunogen
vaccin
plant
fruit
suscept
microbi
infest
would
affect
stabil
vaccin
baculovirusinsect
cell
express
system
also
wide
use
vlp
product
van
oer
et
al
insect
cell
employ
express
sever
vlpbase
vaccin
notabl
one
current
hpv
vaccin
cervarix
r
baculovirusinsect
cell
system
use
manufactur
nonenvelop
envelop
vlp
tabl
variou
hcv
vlp
success
produc
use
system
tabl
baumert
et
al
wellnitz
et
al
choi
et
al
zhao
et
al
insect
cell
system
perform
eukaryotictyp
ptm
support
high
express
level
foreign
protein
advantag
lack
mammalian
pathogen
roy
noad
kushnir
et
al
express
core
protein
recombin
baculoviru
system
result
format
recombin
viru
particl
baumert
et
al
baumert
et
al
baumert
et
al
capabl
induc
antibodi
cellmedi
immun
respons
immun
rabbit
major
disadvantag
system
contamin
product
coproduc
envelop
baculoviru
particl
buonaguro
et
al
palomar
ramirez
requir
develop
complex
stringent
vlp
purif
system
anoth
limit
system
insect
cell
perform
simpler
nglycosyl
compar
mammalian
cell
troublesom
vaccin
develop
correct
glycosyl
often
necessari
optimum
immunogen
vaccin
antigen
kost
et
al
orlova
et
al
puriti
potenc
consist
particl
elimin
host
cell
cultur
media
contamin
crucial
downstream
process
vlpbase
vaccin
addit
purif
method
robust
costeffect
scalabl
prefer
applic
wide
varieti
vlp
viru
like
particl
purifi
use
method
origin
develop
purif
virus
particl
purifi
base
size
densiti
use
ultracentrifug
sucros
cscl
gradient
vicent
et
al
howev
ultracentrifugationbas
method
practic
larg
scale
vaccin
develop
nonscal
tediou
highli
labor
intens
furthermor
use
cscl
problemat
due
toxic
reduc
infect
virus
particl
deform
burova
ioff
due
limit
current
trend
move
away
tradit
vlp
purif
method
toward
scalabl
sophist
techniqu
chromatographi
morenweis
vicent
et
al
crude
lysat
initi
clarifi
lowspe
centrifug
tangenti
flow
filtrat
prior
chromatographi
ion
exchang
affin
sizeexclus
chromatographi
provid
conveni
practic
intermedi
step
captur
concentr
vlp
cellular
media
contamin
morenweis
path
hcv
vaccin
fraught
difficulti
mainli
virul
natur
viru
abil
evad
immun
respons
due
heterogen
howev
advanc
technolog
understand
natur
cours
hcv
infect
pathogenet
mechan
immunolog
marker
correl
resolut
infect
protect
provid
use
inform
vaccin
design
vlp
vaccin
mani
favor
immunolog
characterist
make
promis
hcv
vaccin
candid
current
vlpbase
hcv
vaccin
progress
human
clinic
trial
howev
vlpbase
vaccin
prevent
hbv
hpv
infect
alreadi
licens
support
develop
vlpbase
vaccin
hcv
hcv
vlpbase
vaccin
candid
develop
far
gener
promis
data
preclin
anim
studi
wide
known
sever
factor
includ
express
system
affect
qualiti
product
yield
viral
particl
sever
express
system
effect
use
produc
vlp
vaccin
candid
vlpbase
hcv
vaccin
candid
chimer
hbvhcv
vlp
produc
use
alreadi
establish
product
system
bacteri
yeast
howev
particl
contamin
residu
host
cell
factor
lipid
nucleic
acid
protein
may
stimul
innat
immun
respons
andor
reduc
specif
adapt
immun
respons
therefor
may
signific
impact
vlpbase
vaccin
develop
could
present
bottleneck
develop
vlp
produc
use
mammalian
cell
offer
altern
system
support
appropri
complex
mammaliantyp
ptm
perform
authent
assembl
fold
recombin
protein
therefor
gener
vlp
similar
authent
hcv
virion
howev
difficulti
scale
system
highproduct
cost
might
direct
choic
toward
cost
effect
altern
product
system
genet
vaccin
express
hcvrecombin
vlp
hand
attract
candid
product
high
qualiti
plasmid
dna
simpl
inexpens
scaleup
could
advanc
develop
novel
vlpbase
strategi
ultim
hope
newli
develop
vlp
elicit
specif
strong
respons
hcv
prevent
contain
infect
encourag
result
preclin
anim
studi
suggest
possibl
develop
vaccin
although
may
yet
way
mm
conceiv
initi
draft
manuscript
dw
jt
eg
bgb
revis
mani
part
manuscript
contribut
final
manuscript
